1. ¹Program for Evolutionary Dynamics, Harvard University, Cambridge, MA 02138, USA
2. ²Society of Fellows, Harvard University, Cambridge, MA 02138, USA

Correspondence: Dr F Michor, Society of Fellows, Harvard University, Cambridge, MA 02138, USA. E-mail: michor@fas.harvard.edu

Received 8 May 2006; Revised 10 July 2006; Accepted 13 July 2006; Published online 10 October 2006.

Abstract

Improved understanding of the molecular underpinnings of cancer initiation and progression has led to the development of targeted cancer therapies. The importance of these new methods of cancer treatment necessitates further research into the dynamic interactions between cancer cells and therapeutic agents, as well as a means of analysing their relationship quantitatively. The present review outlines the application of mathematical modelling to the dynamics of targeted cancer therapy, focusing particular attention on chronic myeloid leukaemia and its treatment with imatinib (Glivec).